Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Biotech
Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus
The move balances the number of candidates in Cullinan’s pipeline, which now encompasses four named assets across autoimmune and cancer indications.
Fraiser Kansteiner
Nov 6, 2025 1:26pm
Boehringer's deal frenzy continues with $570M autoimmune pact
Nov 4, 2025 8:00am
Zymeworks drops clinical-stage TCE over benefit-risk profile
Sep 2, 2025 8:10am
Boehringer 'crossing fingers' ahead of 2 key FDA approvals
Jul 24, 2025 3:00am
Otsuka's $670M pact to point Harbour's TCE to autoimmune disease
Jun 23, 2025 6:29am
Cullinan's $700M pact for BCMA bispecific to pair with other TCE
Jun 5, 2025 4:38am
